Transplantační medicína

In this panel Prof. Chantal Mathieu facilitated the discussion with Prof. Ezio Bonifacio, Prof. Thomas Kay, and Prof. John Wentworth. The speakers discussed biomarker-driven type 1 diabetes care, focusing on screening, diagnosis, and monitoring using autoantibodies, C-peptide, and glucose metrics. The panel highlighted the importance of early detection and risk stratification, reviewed immune-targeted therapies and emerging technologies, and emphasized key decision points supporting personalized, biomarker-guided T1D management. 

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Inflamed or Informed? The Great Biomarker Debate

Recorded on 28 March 2026

Technical University of Munich, Munich, Germany

Professor of Clinical Diabetes and Metabolism Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK

Professor of Endocrinology, Sapienza University of Rome, Rome, Italy

Professor of Immunology, Institut Necker Enfants Malades-INEM, Paris, France

Professor of Internal Medicine, Head of Diabetes, San Raffaele Vita Salute University Hospital, Milan, Italy​

INSERM, French Institute of Health and Medical Research, Paris, France